TC
NWBO

Telemus Capital’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Telemus Capital’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-32,401
Closed -$18K – 365
2016
Q3 		$18K Buy
32,401
+17,909
+124% +$8.19K ﹤0.01% 340
2016
Q2 		$8K Buy
+14,492
New +$15.5K ﹤0.01% 340

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Telemus Capital's NWBO Position: Q4 2016 in Review

Telemus Capital sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 32,401 shares — an estimated $18K sold.

Telemus Capital first reported a position in NWBO in Q2 2016 and held it in 2 quarters. The position peaked at $18K in Q3 2016. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Telemus Capital reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Telemus Capital sold 32,401 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $18K.
  • Telemus Capital first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2016 and held it in 2 quarters.
  • Telemus Capital's Northwest Biotherapeutics, Inc. Common stock position peaked at $18K in Q3 2016.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Telemus Capital's 13F filing for Q4 2016, filed 24 Jan 2017.